Board of Directors

Born in 1965. Chairman of the Board since 2023.

Julian has more than 25 years of experience in finance and international business development within the pharmaceutical and technology industries including Oasmia Pharmaceutical AB. Julian is an entrepreneur who ran his own companies for many years in several different business areas, primarily pharmaceutical development. Is an active investor and through companies also a major owner in a number of listed companies.

Number of shares *): 25,677,309
shares through Maida Vale Capital AB
TO4 warrants: 9,375,000 through Maida Vale Capital AB

Education: Economist

Other assignments: Chairman of the board of Maida Vale Capital AB and Hunterhex AB.

Independent in relation to the company and its management but not to major shareholders. 

Born in 1969. Board member since 2021.

Anders has more than 25 years of experience within international finance and business development in the pharmaceutical– and medical device industries. His experience includes Business- and Corporate Development from Pharmacia & Upjohn, Q-Med AB (publ), partner and CEO at venture  capital firm Nexttobe AB and Executive VP and CFO at Oasmia Pharmaceutical AB (publ). In addition, Anders has extensive board experience from pharma- and tech sectors including, but not limited to, Hansa Biopharma AB (publ), Biolamina AB, Delta Projects AB,  Selego AB. 

Number of shares *): 23,284

Education: BSc in Business Administration and Economics at Uppsala University  

Ongoing assignments: Chairman of the board of Rosland Nordic AB, Globopetz AB and Peptonic Medical AB (publ), board member of Terranet AB (publ) and Wonderboo AB (publ).

Independent in relation to the company and its management but not to major shareholders. 

Born in 1956. Board member since 2020.

Per-Göran has 35 years of experience from the pharmaceutical industry. He has extensive experience in pharmacology and neuropharmacology from Kabi, Kabi Pharmacia, Pharmacia & Upjohn and Pharmacia, AstraZeneca and Albireo. Per-Göran is the founder of Albireo AB and was VP Development for Albireo Pharma Inc and its subsidiary Albireo AB and is affiliated with the Division of Translational Alzheimer Neurobiology, Karolinska Institute, Stockholm.

Number of shares *): 125,202 shares and 213,331 shares through company
TO4 warrants: 46,950 and 79,998 warrants through company

Education: MSc in Chemistry, PhD in Medical Science, Adjunct Professor of Neuroscience at Uppsala University

Ongoing assignments: Board member of Dicot AB and Wissboda Gård AB.

Independent in relation to both the company and its management as well as to major shareholders.

Born in 1965. Board member since 2015.

Clas is MD. Associate Professor. Senior consultant MS-Center, Dept Neurology. CMO Laboratory for Clinical immunology, Sahlgrenska University Hospital, Sweden.

Since 2001 he has conducted research within Multiple Sclerosis (MS) at the hospital’s Multiple sclerosis centre and the Department of Clinical Neuroscience, University of Gothenburg. In addition to academic research, he has participated in several clinical drug trials in MS led by Biogen-Idec, Merck, Novartis, Roche and Sanofi, several of which resulted in today’s standard treatments for MS.

Number of shares *): 40,000 shares
TO4 warrants: 15,000

Education: MD and PhD in Medicine at University of Gothenburg, Sweden.

Other assignments: –

Independent in relation to both the company and its management as well as to major shareholders.

Born in 1961. Board member since 2018.

Carol is an R&D and drug development expert with over 35 years of experience in major pharmaceutical and biotechnology companies in the UK and US, as well as the venture capital and non-profit sectors, focusing on drug acquisition and profiling of NcE and biologics. Combining preclinical and clinical experience in central nervous system and immunoinflammatory drugs, she has the advantage of applying a strong scientific foundation and an innovative experimental medicine approach to clinical development to obtain early proof of mechanism/concept. Carol is currently the Medical and Scientific Director of Brandaris Therapeutics, a neuropsychiatry-focused biotechnology company founded by BGV. She has held leadership roles at Syntex, Wyeth, BTG, GSK and SmallPharma, including leading drug development across multiple therapeutic areas but with a strong focus on neuroscience diseases and an emphasis on translational medicine. Dr. Routledge has also held the role of Chief Research Officer at Alzheimer’s Research UK (ARUK, during which time she founded a global initiative focused on early detection of neurodegenerative diseases (EDoN). She took up the role of CEO of a subsidiary of ARUK.

Number of shares: –

Education: BSc, in Biology/Zoology at Nottingham University, UK, and PhD in Neuroscience/Neuropharmacology at Queens Medical School, Nottingham, UK.

Ongoing assignments: –

Independent in relation to both the company and its management as well as to major shareholders.

Born in 1957. Board member since 2018.

Anders has held several senior roles in Astra, AstraZeneca, CV Therapeutics, Actogenics and Tikomed AB. He has previous experience in management, business development, financing and pharmaceutical development.

Number of shares: –

Education: DDS (Doctor of Dental Surgery) at University of Umeå

Ongoing assignments: Chairman of the of Mucolife Therapeutics AB.  Board member of Nexus BioSciences AB and, Anders Waas AB.

Independent in relation to both the company and its management and dependent of major shareholders.